NCT03989635View on ClinicalTrials.gov

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 15, 2019

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
AsthmaAsthma, BronchialBronchial AsthmaEosinophiliaPhysiological Effects of Drugs
Interventions
DRUG

QAW039

QAW039 450mg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY